RÉSUMÉ
On the basis of the recent findings about the biological properties of thiazolidinones and taking into account the encouraging results about the antifungal activity of some (thiazol-2-yl)hydrazines, new N-substituted heterocyclic derivatives were designed combining the thiazolidinone nucleus with the hydrazonic portion. In details, 1,3-thiazolidin-4-ones bearing (cyclo)aliphatic or (hetero)aromatic moieties linked to the N1-hydrazine at C2 were synthesized and classified into three series according to the aromatic or bicyclic rings connected to the lactam nitrogen of the thiazolidinone. These molecules were assayed for their anti-Candida effects in reference to the biological activity of the conventional topic (clotrimazole, miconazole, tioconazole) and systemic drugs (fluconazole, ketoconazole, amphotericin B). Finally, we investigated the selectivity against fungal cells by testing the compounds endowed with the best MICs on Hep2 cells in order to assess their cell toxicity (CC50) and we noticed that two derivatives were less cytotoxic than the reference drug clotrimazole. Moreover, a preliminary molecular modelling approach has been performed against lanosterol 14-α demethylase (CYP51A1) to rationalize the activity of the tested compounds and to specify the target protein or enzyme.
Sujet(s)
Antifongiques/composition chimique , Antifongiques/pharmacologie , Candida/effets des médicaments et des substances chimiques , Thiazolidines/composition chimique , Inhibiteurs de la 14-alpha déméthylase/composition chimique , Inhibiteurs de la 14-alpha déméthylase/pharmacologie , Antibactériens/composition chimique , Antibactériens/pharmacologie , Techniques de chimie synthétique , Conception de médicament , Évaluation préclinique de médicament/méthodes , Protéines fongiques/antagonistes et inhibiteurs , Protéines fongiques/composition chimique , Protéines fongiques/métabolisme , Cellules HepG2/effets des médicaments et des substances chimiques , Humains , Tests de sensibilité microbienne , Simulation de docking moléculaire , Bibliothèques de petites molécules/composition chimique , Bibliothèques de petites molécules/pharmacologie , Sterol 14-demethylase/composition chimique , Sterol 14-demethylase/métabolisme , Relation structure-activité , Thiazolidines/pharmacologieRÉSUMÉ
We designed and synthesized a large number of novel thiazolidin-4-one derivatives for the evaluation of their anti-Toxoplasma gondii activity. This scaffold was functionalized at the N1-hydrazine portion with aliphatic, cycloaliphatic and (hetero)aromatic moieties. Then, a benzyl pendant was introduced at the lactamic NH of the core nucleus to evaluate the influence of this chemical modification on biological activity. The compounds were subjected to several in vitro assays to assess their anti-parasitic efficacy, cytotoxicity on fibroblasts, inhibition of tachyzoite invasion/attachment and replication after treatment. Results showed that fourteen of these thiazole-based compounds compare favorably to control compound trimethoprim in terms of parasite growth inhibition.
Sujet(s)
Antiprotozoaires/pharmacologie , Conception de médicament , Thiazolidines/pharmacologie , Toxoplasma/effets des médicaments et des substances chimiques , Antiprotozoaires/synthèse chimique , Antiprotozoaires/composition chimique , Relation dose-effet des médicaments , Structure moléculaire , Tests de sensibilité parasitaire , Relation structure-activité , Thiazolidines/synthèse chimique , Thiazolidines/composition chimiqueRÉSUMÉ
Acetylation, which targets a broad range of histone and non-histone proteins, is a reversible mechanism and plays a critical role in eukaryotic genes activation/deactivation. Acetyltransferases are very well conserved through evolution. This allows the use of a simple model organism, such as budding yeast, for the study of their related processes and to discover specific inhibitors. Following a simple yeast-based chemogenetic approach, we have identified a novel HAT (histone acetyltransferase) inhibitor active both in vitro and in vivo. This new synthetic compound, 1-(4-(4-chlorophenyl)thiazol-2-yl)-2-(propan-2-ylidene)hydrazine, named BF1, showed substrate selectivity for histone H3 acetylation and inhibitory activity in vitro on recombinant HAT Gcn5 and p300. Finally, we tested BF1 on human cells, HeLa as control and two aggressive cancer cell lines: a neuroblastoma from neuronal tissue and glioblastoma from brain tumour. Both global acetylation of histone H3 and specific acetylation at lysine 18 (H3AcK18) were lowered by BF1 treatment. Collectively, our results show the efficacy of this novel HAT inhibitor and propose the utilization of BF1 as a new, promising tool for future pharmacological studies.
Sujet(s)
Histone acetyltransferases/antagonistes et inhibiteurs , Histone acetyltransferases/synthèse chimique , Thiazoles/synthèse chimique , Acétylation , Lignée cellulaire tumorale , Cellules HeLa , Humains , Thiazoles/composition chimiqueRÉSUMÉ
Monoamine oxidases (MAOs) are mitochondrial bound enzymes, which catalyze the oxidative deamination of monoamine neurotransmitters. Inside the brain, MAOs are present in two isoforms: MAO-A and MAO-B. The activity of MAO-B is generally higher in patients affected by neurodegenerative diseases like Alzheimer's and Parkinson's. Therefore, the search for potent and selective MAO-B inhibitors is still a challenge for medicinal chemists. Nature has always been a source of inspiration for the discovery of new lead compounds. Moreover, natural medicine is a major component in all traditional medicine systems. In this review, we present the latest discoveries in the search for selective MAO-B inhibitors from natural sources. For clarity, compounds have been classified on the basis of structural analogy or source: flavonoids, xanthones, tannins, proanthocyanidins, iridoid glucosides, curcumin, alkaloids, cannabinoids, and natural sources extracts. MAO inhibition values reported in the text are not always consistent due to the high variability of MAO sources (bovine, pig, rat brain or liver, and human) and to the heterogeneity of the experimental protocols used.
Sujet(s)
Produits biologiques/pharmacologie , Inhibiteurs de la monoamine oxydase/pharmacologie , Monoamine oxidase/métabolisme , Animaux , Produits biologiques/composition chimique , Humains , Inhibiteurs de la monoamine oxydase/composition chimique , Relation structure-activitéRÉSUMÉ
Thirty-eight new (4-(4-substituted-phenyl/2,4-disubstituted-phenyl)-thiazol-2-yl)hydrazine derivatives were synthesized in good yield and assayed for their in vitro anti-Candida activity, compared to topical and systemic antifungal drugs, against twenty-two clinical isolates of Candida spp. The concurrent presence of aliphatic chains or cycloaliphatic rings at N1-hydrazine and a 4-methyl/4-methoxyphenyl at C4 position of the thiazole nucleus exhibited an interesting anti-Candida inhibitory activity. Moreover, some of the most active compounds showed synergistic antifungal effects and lower cell toxicity when combined with clotrimazole.
Sujet(s)
Antifongiques/pharmacologie , Candida/effets des médicaments et des substances chimiques , Hydrazines/pharmacologie , Thiazoles/pharmacologie , Antifongiques/synthèse chimique , Antifongiques/composition chimique , Survie cellulaire/effets des médicaments et des substances chimiques , Relation dose-effet des médicaments , Cellules HepG2 , Humains , Hydrazines/synthèse chimique , Hydrazines/composition chimique , Tests de sensibilité microbienne , Structure moléculaire , Relation structure-activité , Thiazoles/synthèse chimique , Thiazoles/composition chimiqueRÉSUMÉ
A large series of (4-substituted-thiazol-2-yl)hydrazine derivatives was synthesized in good yield and assayed for their in vitro human monoamine oxidase (hMAO) inhibitory activity and selectivity. Most of them showed inhibitory activity in the nanomolar range and hMAO-B selective inhibition higher than reference drugs, demonstrating our interest in this privileged scaffold. The structure-activity relationship of the different rings on the N1-hydrazine position indicated that a pyridine ring was preferred with the presence of electron-withdrawing substituents on the aryl group at C4 of the thiazole nucleus. The substituent on the α-carbon to the N1-hydrazine moiety (methyl or hydrogen) had a great influence on the activity and hMAO-B selectivity. Moreover, the reversibility of the enzyme inhibition for the best active compound was reported.
Sujet(s)
Hydrazines/pharmacologie , Inhibiteurs de la monoamine oxydase/pharmacologie , Monoamine oxidase/métabolisme , Relation dose-effet des médicaments , Humains , Hydrazines/synthèse chimique , Hydrazines/composition chimique , Structure moléculaire , Inhibiteurs de la monoamine oxydase/synthèse chimique , Inhibiteurs de la monoamine oxydase/composition chimique , Relation structure-activitéRÉSUMÉ
Novel 1-(4-ethyl carboxylate-thiazol-2-yl)-3,5-di(hetero)aryl-2-pyrazoline derivatives were obtained by reacting 3,5-di(hetero)aryl-1-thiocarbamoyl-2-pyrazolines with the ethyl ester of α-bromo-pyruvic acid. The synthesized compounds were confirmed by spectroscopic data and assayed to evaluate their in vitro ability to inhibit both isoforms of human cyclooxygenase (hCOX). Some derivatives (compounds 5, 6, 13, 16, and 17) displayed promising selectivity against hCOX-1 in the micromolar range and were shown to have a selectivity index similar or better than the reference drugs (indometacin, diclofenac). The introduction of a phenyl or a 4-F-phenyl ring on the C5 associated with a 4-substituted phenyl or a heteroaryl group on the C3 of (4-substituted-thiazol-2-yl)pyrazoline derivatives improved the activity against hCOX-1. Thanks to these preliminary results it could be possible to extend our knowledge of the pharmacophoric requirements for the discovery of new pyrazoline-based hCOX-1 inhibitors.
Sujet(s)
Cyclooxygenase 1/métabolisme , Inhibiteurs des cyclooxygénases/synthèse chimique , Pyrazoles/synthèse chimique , Thiazoles/synthèse chimique , Plaquettes/effets des médicaments et des substances chimiques , Plaquettes/enzymologie , Inhibiteurs des cyclooxygénases/composition chimique , Inhibiteurs des cyclooxygénases/pharmacologie , Découverte de médicament , Humains , Microsomes/effets des médicaments et des substances chimiques , Microsomes/enzymologie , Structure moléculaire , Pyrazoles/composition chimique , Pyrazoles/pharmacologie , Relation structure-activité , Thiazoles/composition chimique , Thiazoles/pharmacologieRÉSUMÉ
INTRODUCTION: Monoamine oxidase (MAO) plays an important role in the control of intracellular concentration of monoaminergic neurotransmitters or neuromodulators and dietary amines. The rapid degradation of these molecules ensures the proper functioning of synaptic neurotransmission and is critical for the regulation of several mental and cognitive functions. The by-products of MAO-mediated reactions comprehend reactive and toxic chemical species. As a consequence of this, the development of human MAO inhibitors led to important discoveries in the treatment of several neuropsychiatric and neurodegenerative disorders. AREAS COVERED: This review highlights the recent MAO inhibitors-related patents (2010-2012) and reports on new associations of already known MAO inhibitors with other drugs, innovative therapeutic targets, MAO inhibitors obtained by plants extraction, alternative administration routes and synthetic processes. EXPERT OPINION: MAO inhibitors appear promising for further clinical development being often endowed with other pharmacological functions (iron-chelating property, cholinesterase inhibition). A new 'golden age' of MAO inhibitors recently started from (i) the discovery of new therapeutic targets (prostate cancer, diabetes, ischemia/reperfusion injury, tobacco dependence, transmissible spongiform encephalopathy); (ii) the recognized role of MAO as biomolecular markers (insomnia, chronic alcoholism, obsessive-compulsive behavior); (iii) the activity of these enzymes in other tissues (platelets, prostate cells).
Sujet(s)
Troubles mentaux/traitement médicamenteux , Inhibiteurs de la monoamine oxydase/pharmacologie , Maladies neurodégénératives/traitement médicamenteux , Animaux , Systèmes de délivrance de médicaments , Conception de médicament , Humains , Troubles mentaux/physiopathologie , Monoamine oxidase/effets des médicaments et des substances chimiques , Monoamine oxidase/métabolisme , Maladies neurodégénératives/physiopathologie , Brevets comme sujetRÉSUMÉ
Novel (4-(4-iodophenyl)-thiazol-2-yl)hydrazine derivatives were assayed for their in vitro anti-Candida activity, compared to topical and systemic antifungal drugs, against twenty-seven clinical isolates. The presence of aliphatic chains or specific heteroaromatic rings on hydrazone moiety at position C2 and a 4-iodophenyl at C4 of the thiazole ring gave a promising inhibitory activity especially against Candida albicans and Candida krusei. The most active compounds have been also evaluated for their cytotoxicity and in association with clotrimazole for anti-Candida activity.
Sujet(s)
Antibactériens/synthèse chimique , Antibactériens/pharmacologie , Antifongiques/synthèse chimique , Antifongiques/pharmacologie , Candida/effets des médicaments et des substances chimiques , Hydrazines/synthèse chimique , Hydrazines/pharmacologie , Antibactériens/composition chimique , Antibactériens/toxicité , Antifongiques/composition chimique , Antifongiques/toxicité , Bactéries/effets des médicaments et des substances chimiques , Survie cellulaire/effets des médicaments et des substances chimiques , Techniques de chimie synthétique , Cellules HepG2 , Humains , Hydrazines/composition chimique , Hydrazines/toxicité , Tests de sensibilité microbienneRÉSUMÉ
A computer-aided design of novel asymmetric pyrazoles with improved enantioselective properties was performed by docking experiments starting from a model of Chiralcel OJ chiral in the stationary phase. Synthesis and HPLC experiments confirmed the theoretical prediction and led to a detailed investigation of the enantioselective recognition process. For the first time, looking at the time spent by each enantiomer in contact with the CSP during long molecular dynamic simulations, the experimental analytical trend has been reproduced.
Sujet(s)
Chromatographie en phase liquide à haute performance/méthodes , Conception de médicament , Simulation de dynamique moléculaire , Pyrazoles/composition chimique , Conformation moléculaire , Pyrazoles/isolement et purification , Stéréoisomérie , Spécificité du substrat , ThermodynamiqueRÉSUMÉ
Monoamine oxidase B (MAO-B) is a promising target for the treatment of neurodegenerative disorders. We report the synthesis and the biological evaluation of halogenated derivatives of 1-aryliden-2-(4-phenylthiazol-2-yl)hydrazines. The fluorinated series shows interesting activity and great selectivity toward the human recombinant MAO-B isoform expressed in baculovirus infected BTI insect cells. The multiple crystal structures alignment of the enzyme highlighted pronounced induced fit (IF) adaptations with respect to bound ligands. Therefore, IF docking (IFD) experiments and molecular dynamic (MD) simulations were carried out to reveal the putative binding mode and to explain the experimentally observed differences in the activity of 1-(aryliden-2-(4-(4-chlorophenyl)thiazol-2-yl)hydrazines. The importance of water molecules within the binding site was also investigated. These are known to play an important role in the binding site cavity and to mediate protein-ligand interactions. Detailed analyses of the trajectories provide insights on the chemical features required for the activity of this scaffold. In particular it was highlighted the importance of fluorine atom interacting with the water close to the cofactor and the influence of steric bulkiness of substituents in the arylidene moiety. Free energy perturbation (FEP) analysis confirmed experimental data. The information we deduced will help to develop novel high-affinity MAO-B inhibitors.
Sujet(s)
Hydrazones/synthèse chimique , Hydrazones/pharmacologie , Inhibiteurs de la monoamine oxydase/synthèse chimique , Monoamine oxidase/métabolisme , Thiazoles/synthèse chimique , Thiazoles/pharmacologie , Sites de fixation , Humains , Hydrazones/composition chimique , Spectroscopie par résonance magnétique , Modèles moléculaires , Simulation de dynamique moléculaire , Inhibiteurs de la monoamine oxydase/composition chimique , Inhibiteurs de la monoamine oxydase/pharmacologie , Maladie de Parkinson/traitement médicamenteux , Conformation des protéines , Relation structure-activité , Spectrométrie de masse en tandem , Thiazoles/composition chimiqueRÉSUMÉ
Among different heterocyclic chemotypes incorporating two nitrogen atoms, pyrazolines could be considered a valid pharmacophore for the synthesis of selective monoamine oxidase (MAO) inhibitors because they were developed by the cyclization of the early hydrazine derivatives such as isocarboxazid. Substituted pyrazolines, decorated with different functional groups, are important lead compounds endowed with a large amount of biological activities. As a matter of this, most of them were also evaluated as dual inhibitors with a synergistic action towards different classes of enzymes (ciclooxygenase, acetylcholinesterase, butyrylcholinesterase). Moreover due to the direct correlation with the recognized MAO inhibition, this scaffold displayed antidepressant and anticonvulsant properties in animal models.
Sujet(s)
Inhibiteurs de la monoamine oxydase/pharmacologie , Monoamine oxidase/métabolisme , Maladies neurodégénératives/traitement médicamenteux , Pyrazoles/pharmacologie , Animaux , Humains , Modèles moléculaires , Simulation de dynamique moléculaire , Monoamine oxidase/composition chimique , Inhibiteurs de la monoamine oxydase/synthèse chimique , Inhibiteurs de la monoamine oxydase/composition chimique , Maladies neurodégénératives/enzymologie , Pyrazoles/synthèse chimique , Pyrazoles/composition chimique , Relation quantitative structure-activitéRÉSUMÉ
PURPOSE: We previously identified novel thiazole derivatives able to reduce histone acetylation and histone acetyltransferase (HAT) activity in yeast. Among these compounds, 3-methylcyclopentylidene-[4-(4'-chlorophenyl)thiazol-2-yl]hydrazone (CPTH6) has been selected and used throughout this study. EXPERIMENTAL DESIGN: The effect of CPTH6 on histone acetylation, cell viability and differentiation, cell-cycle distribution, and apoptosis in a panel of acute myeloid leukemia and solid tumor cell lines has been evaluated. RESULTS: Here, we showed that CPTH6 leads to an inhibition of Gcn5 and pCAF HAT activity. Moreover, it inhibits H3/H4 histones and α-tubulin acetylation of a panel of leukemia cell lines. Concentration- and time-dependent inhibition of cell viability, paralleled by accumulation of cells in the G(0)/G(1) phase and depletion from the S/G(2)M phases, was observed. The role of mitochondrial pathway on CPTH6-induced apoptosis was shown, being a decrease of mitochondrial membrane potential and the release of cytochrome c, from mitochondria to cytosol, induced by CPTH6. Also the involvement of Bcl-2 and Bcl-xL on CPTH6-induced apoptosis was found after overexpression of the two proteins in leukemia cells. Solid tumor cell lines from several origins were shown to be differently sensitive to CPTH6 treatment in terms of cell viability, and a correlation between the inhibitory efficacy on H3/H4 histones acetylation and cytotoxicity was found. Differentiating effect on leukemia and neuroblastoma cell lines was also induced by CPTH6. CONCLUSIONS: These results make CPTH6 a suitable tool for discovery of molecular targets of HAT and, potentially, for the development of new anticancer therapies, which warrants further investigations.
Sujet(s)
Antinéoplasiques/pharmacologie , Apoptose/effets des médicaments et des substances chimiques , Histone/métabolisme , Maturation post-traductionnelle des protéines/effets des médicaments et des substances chimiques , Thiazoles/pharmacologie , Facteurs de transcription CBP-p300/antagonistes et inhibiteurs , Acétylation , Animaux , Antinéoplasiques/effets indésirables , Protéines régulatrices de l'apoptose/métabolisme , Cycle cellulaire/effets des médicaments et des substances chimiques , Différenciation cellulaire/effets des médicaments et des substances chimiques , Lignée cellulaire tumorale , Survie cellulaire/effets des médicaments et des substances chimiques , Humains , Leucémie aigüe myéloïde , Souris , Neuroblastome , Thiazoles/effets indésirables , Tubuline/métabolismeRÉSUMÉ
Several 3-carbonyl (1-26), 3-acyl (27-52), and 3-carboxyhydrazido (53-58) coumarins have been synthesized in high yields (72-99%) and tested in vitro for their human monoamine oxidase A and B (hMAO-A and hMAO-B) inhibitory activity. Different substituents on the coumarin nucleus were evaluated for their effect on biological activity and isoform selectivity. Substitution at position C7 of the 3-ethyl ester coumarin ring, or the introduction of a hydrazido substituent at C3, were important to obtain highly potent and selective hMAO-B inhibitors with IC(50) values in the nanomolar range. Some derivatives were also submitted to a stability test and showed no chemical cleavage in vitro.
Sujet(s)
Coumarines/composition chimique , Coumarines/pharmacologie , Inhibiteurs de la monoamine oxydase/composition chimique , Inhibiteurs de la monoamine oxydase/pharmacologie , Monoamine oxidase/métabolisme , Coumarines/synthèse chimique , Humains , Concentration inhibitrice 50 , Modèles moléculaires , Monoamine oxidase/composition chimique , Inhibiteurs de la monoamine oxydase/synthèse chimique , Relation structure-activitéRÉSUMÉ
A set of ten C5-chiral 4,5-dihydro-(1H)-pyrazole derivatives was synthesized and analyzed by high-performance liquid chromatography (HPLC) on the polysaccharide-based Chiralcel OJ-H chiral stationary phase (CSP). The enantioseparations were carried out using pure ethanol as eluent. Different structural elements of the investigated compounds were recognized for obtaining a very high enantioselectivity. In order to clarify some aspects of the chiral discrimination process, the thermodynamic parameters associated to the enantiorecognition and the enantiomer elution order were established.
Sujet(s)
Benzoates/composition chimique , Cellulose/analogues et dérivés , Chromatographie en phase liquide à haute performance/instrumentation , Pyrazoles/composition chimique , Adsorption , Cellulose/composition chimique , Chromatographie en phase liquide à haute performance/méthodes , Structure moléculaire , StéréoisomérieRÉSUMÉ
A series of homoisoflavonoids [(E)-3-benzylidenechroman-4-ones 1a-w, 3-benzyl-4H-chromen-4-ones 2a-g, and 3-benzylchroman-4-ones 3a-e] have been synthesized and tested in vitro as inhibitors of human monoamine oxidase isoforms A and B (hMAO-A and hMAO-B). Most of the compounds were found to be potent and selective MAO-B inhibitors. In general, the (E)-3-benzylidenechroman-4-ones 1a-w showed activities in the nano- or micromolar range coupled with high selectivity against hMAO-B. The reduction of the exocyclic double bond results in compounds 3a-e selective against isoform B and active in the micromolar range. In contrast, the endocyclic migration of the double bond (compounds 2a-g) generally produces the loss of the inhibitory activity or a marked reduction in potency. (E)-3-(4-(Dimethylamino)benzylidene)chroman-4-one (1l) and (E)-5,7-dihydroxy-3-(4-hydroxybenzylidene)chroman-4-one (1h) were the most interesting compounds of the entire series of inhibitors, showing hMAO-B affinity better than the selective inhibitor selegiline. Molecular modeling studies have been carried out to explain the selectivity of the most active homoisoflavonoids 1h and 1l.
Sujet(s)
Découverte de médicament , Flavonoïdes/composition chimique , Flavonoïdes/pharmacologie , Inhibiteurs de la monoamine oxydase/composition chimique , Inhibiteurs de la monoamine oxydase/pharmacologie , Monoamine oxidase/métabolisme , Flavonoïdes/synthèse chimique , Flavonoïdes/métabolisme , Humains , Concentration inhibitrice 50 , Modèles moléculaires , Monoamine oxidase/composition chimique , Inhibiteurs de la monoamine oxydase/synthèse chimique , Inhibiteurs de la monoamine oxydase/métabolisme , Conformation des protéines , Spécificité du substratRÉSUMÉ
A new series of [4-(4'-substituted-phenyl)thiazol-2-yl]hydrazine derivatives were synthesized in good yield (86-99%) and characterized by elemental analysis, IR, (1)H NMR, and mass spectral studies. The compounds were assayed for their in vitro broad-spectrum antifungal activity, compared to clotrimazole and fluconazole, against 20 clinical isolates of pathogenic Candida spp., representing five different species. The results showed that the presence of heterocyclic or bicyclic rings on hydrazone moiety in position C2 of thiazole revealed a promising selective inhibitory activity especially against Candida albicans and Candida glabrata.
Sujet(s)
Antifongiques/composition chimique , Antifongiques/pharmacologie , Candida/effets des médicaments et des substances chimiques , Thiazoles/composition chimique , Thiazoles/pharmacologie , Antifongiques/synthèse chimique , Évaluation préclinique de médicament , Tests de sensibilité microbienne , Thiazoles/synthèse chimiqueRÉSUMÉ
Eighteen new 1-N-substituted-3,5-diphenyl-2-pyrazoline derivatives have been synthesized and cyclooxygenase (COX-1 and COX-2) inhibitory activities have been evaluated. The results of these biological assays showed that all of new derivatives are not endowed with improved anti-inflammatory activity against COX-1, but some of them showed a good activity against COX-2. To evaluate the binding mode of the most significative compounds (2d, 2f, 2g and 2k) docking studies were carried out. These studies confirmed biological data, in fact these compounds were able to fit into the active site of COX-2.
Sujet(s)
Inhibiteurs de la cyclooxygénase 2/synthèse chimique , Inhibiteurs de la cyclooxygénase 2/pharmacologie , Cyclooxygenase 2/métabolisme , Pyrazoles/pharmacologie , Animaux , Domaine catalytique/effets des médicaments et des substances chimiques , Cyclooxygenase 1/métabolisme , Inhibiteurs de la cyclooxygénase 2/composition chimique , Humains , Insectes , Modèles moléculaires , Structure moléculaire , Pyrazoles/synthèse chimique , Pyrazoles/composition chimique , Stéréoisomérie , Relation structure-activitéRÉSUMÉ
A series of N-substituted-3-[(2'-hydroxy-4'-prenyloxy)-phenyl]-5-phenyl-4,5-dihydro-(1H)-pyrazolines were synthesized and tested on human monoamine oxidase-A and -B isoforms. Structure-activity relationships and molecular modelling showed that some substitutions, such as benzyloxy or chlorine atom, improve the best interaction with active site of hMAO-B.
Sujet(s)
Inhibiteurs de la monoamine oxydase/synthèse chimique , Inhibiteurs de la monoamine oxydase/pharmacologie , Monoamine oxidase/effets des médicaments et des substances chimiques , Prénylation , Pyrazoles/synthèse chimique , Pyrazoles/pharmacologie , Humains , Concentration inhibitrice 50 , Modèles moléculaires , Structure moléculaire , Inhibiteurs de la monoamine oxydase/composition chimique , Pyrazoles/composition chimique , Relation structure-activitéRÉSUMÉ
Novel 1-(4-arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazine derivatives have been investigated for their ability to inhibit selectively the activity of the human B isoform of monoamine oxidase. These compounds were obtained as racemates and (R)-enantiomers by a stereoconservative synthetic pattern in high yield and enantiomeric excess. The (S)-enantiomers of the most active derivatives have been separated by enantioselective HPLC. All compounds showed selective activity against hMAO-B with IC(50) ranging between 21.90 and 0.018 microM.